Status:
UNKNOWN
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
Lead Sponsor:
Universita di Verona
Conditions:
Psoriasis
Metabolic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A prospective, controlled, open trial in psoriasis patients with metabolic syndrome, candidate to methotrexate or secukinumab was conducted between January 2019 and May 2020. The primary end point of ...
Detailed Description
A prospective, non-randomized controlled open trial in psoriasis patients with metabolic syndrome was conducted between January 2019 and May 2020. Inclusion criteria were age ≥ 18 years, being affecte...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- being affected by moderate to severe chronic plaque psoriasis and concomitant metabolic syndrome
- being candidate to systemic treatment with methotrexate or secukinumab according to the Italian guideline for psoriasis
Exclusion
- being affected by psoriatic arthritis, pregnancy, breast feeding,
- having initiated a systemic treatment for psoriasis in the previous 3 months and having a clinical condition that could affect the metabolic parameters other than metabolic syndrome.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04469829
Start Date
August 1 2020
End Date
December 31 2022
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Verona
Verona, Italy, 37126